Shire made another inroad into Latin American markets by obtaining approval from Mexican regulators for Elaprase, a treatment for Hunter syndrome.

The disease is a genetic condition caused by a deficiency in the lysosomal enzyme iduronate-2-sulfatase and can result in organ malfunction and death.

Mexico is the first Latin American country to approve Elaprase (idursulfase). The drug is under review in Brazil.